Enwave Corporation Stock
€0.17
Your prediction
Enwave Corporation Stock
Pros and Cons of Enwave Corporation in the next few years
Pros
Cons
Performance of Enwave Corporation vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enwave Corporation | -8.150% | 15.232% | -13.000% | 9.434% | -26.271% | -48.214% | -79.814% |
| Aurinia Pharmaceuticals Inc. | 0.370% | 6.703% | 11.266% | 79.110% | 0.445% | 33.934% | 21.345% |
| Spectral Medical Inc | 2.960% | -3.333% | 4.819% | 78.279% | 9.434% | 310.377% | 144.382% |
| Xenon Pharmaceuticals Inc. | 0.410% | 2.066% | 35.714% | 70.345% | 30.000% | 48.795% | - |
News
EnWave Reports 2026 First Quarter Consolidated Interim Financial Results
Vancouver, B.C., February 20th, 2026. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the first
EnWave Signs Royalty-Bearing License with Bowen Gumlu Grower’s Association of Australia
Vancouver, B.C., February 2nd, 2026, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today announced that the Company has signed a royalty-bearing commercial license
EnWave Reports 2025 Fourth Quarter and Annual 2025 Consolidated Financial Results
Vancouver, B.C., December 15th, 2025 / EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the fourth

